1. Eli Lilly and Novo Nordisk are leading players in the obesity and diabetes markets, valued at over $100 billion. 2. Both companies have strengths and weaknesses in their drug pipelines compared to competitors. 3. The article compares the long-term attractiveness of Novo Nordisk and Eli Lilly as investment opportunities.